Just days after closing its Seagen acquisition, Pfizer has struck a deal to expand its antibody-drug conjugate portfolio even further.
Nona Announces Collaboration with Evive to Accelerate Antibody Discovery
CAMBRIDGE, Mass., Dec. 3, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, announced today it has entered into a collaboration agreement with Lycia Therapeutics, a leader in extracellular protein degradation. Lycia is using its proprietary lysosomal targeting chimeras (LYTACs) platform to discover and develop first-in-class therapeutics that degrade extracellular and membrane-bound proteins that drive a range of difficult-to-treat diseases. Through the collaboration, Lycia will leverage Nona's proprietary Harbour Mice® HCAb fully human antibody transgenic mice platform to discover novel antibodies for its LYTAC protein degrader therapeutics.
Nona Biosciences Announces Strategic Collaboration with GeneQuantum
CAMBRIDGE, Mass., Oct. 13, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, and INGENIA Therapeutics, a preclinical-stage biotech company with a breakthrough technology to restore defective blood vessels, announced today that they have entered into a collaboration agreement. By harnessing the immense expertise and resources of both companies, the collaboration aims to accelerate the development of innovative therapeutics for immunological disorders with highly unmet needs.
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge technology innovation and provider of integrated solutions from “Idea to IND” (I to ITM), announced it has entered into a strategic collaboration agreement with Massachusetts-based PharmaEssentia Innovation Research Center (PIRC) on Nona’s proprietary Harbour Mice fully human antibody transgenic mice platform.